Stay updated on Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check20 days agoChange DetectedPublication section wording updated to clarify auto-population from PubMed and potential non-relations to the study. Page revision tag updated to Revision: v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check26 days agoChange DetectedThe page no longer displays the generic government funding status notice. This change does not affect the study details, eligibility criteria, or results information.SummaryDifference0.1%

- Check34 days agoChange DetectedIn the Taiwan location entry, 'Tainan City, Taiwan, 70457' was changed to 'Tainan, Taiwan, 70457'.SummaryDifference0.0%

- Check49 days agoChange DetectedNo additions or deletions were detected on the Study Details page for NCT03302234; the content appears unchanged between the two screenshots. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check70 days agoChange Detected- Added a government-operating-status notice and a link to official sources, indicating the page may have dynamic status information. - Updated version from v3.1.0 to v3.2.0, signaling a new release.SummaryDifference1%

- Check77 days agoChange DetectedUpdated to v3.1.0 and removed several MedlinePlus topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) indicating a narrowing of content coverage. The page now reflects the new revision but loses these topics.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial page.